THE NICKLES GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS · Pharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Maryland · House · Senate · $40,000.00 income · posted Oct 20, 2025

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2026, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone.

Defense

National Defense Authorization Act for FY2026, provisions related to biological and chemical defense and access to naloxone.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.